China's Innovent rises as U.S. FDA accepts regulatory submission for sintilimab

Reuters2021-05-18

** Shares of Chinese cancer drug developer Innovent Biologics Inc rise as much as 8% to HK$94, their highest since Feb 22, on course for a third consecutive session of gains

** Stock on track for best day since March 30

** The Jiangsu-based firm says U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer

** Says it is the first U.S. regulatory submission of sintilimab, a PD-1 inhibitor being developed and commercialized under a global collaboration agreement between Innovent and Eli Lilly and Co

** Innovent says it looks to working closely with FDA to potentially bring the sintilimab-pemetrexed-platinum chemotherapy combination as a treatment option in the United States

** The Hong Kong Hang Seng Commerce & Industry Index rises 1.4%, and the healthcare index climbs 1.7%

** Both Hang Seng China enterprises index and the benchmark index rise 1.3%

** As of last close, stock up 6.1% this year

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment